BBIO
BridgeBio Pharma Inc
NASDAQ: BBIO · HEALTHCARE · BIOTECHNOLOGY
$70.94
+1.76% today
Updated 2026-04-29
Market cap
$13.75B
P/E ratio
—
P/S ratio
27.39x
EPS (TTM)
$-3.78
Dividend yield
—
52W range
$32 – $85
Volume
2.5M
BridgeBio Pharma Inc (BBIO) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-144.40%
Operating margin
-83.30%
ROE
-1,790.00%
ROA
-33.80%
Debt/equity
-0.96x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2017 | $0.00 | $-30.57M | — | — | — |
| 2018 | $0.00 | $-130.75M | — | — | — |
| 2019 | $40.56M | $-260.44M | 93.84% | -656.41% | -642.10% |
| 2020 | $8.25M | $-448.72M | 100.00% | -5,751.99% | -5,439.74% |
| 2021 | $69.72M | $-562.54M | 95.53% | -827.12% | -806.90% |
| 2022 | $77.65M | $-481.18M | 95.58% | -659.65% | -619.70% |
| 2023 | $9.30M | $-643.20M | 73.71% | -6,528.75% | -6,913.92% |
| 2024 | $221.90M | $-535.76M | 98.25% | -267.22% | -241.44% |
| 2025 | $502.08M | $-729.31M | 94.37% | -113.35% | -145.26% |